ALBUQUERQUE, N.M., Dec. 12 /PRNewswire/ -- Protalex Inc.
(OTC Bulletin Board: PRTX), a biopharmaceutical firm announces the completion
of an approximate $500,000 private placement of its common stock. The Company
also continues to make substantial progress in its efforts to develop its
unique approach to the management of arthritis. Almost all therapeutic
approaches focus on the end product manifestations of the disease process
which, by their very nature, can only alleviate symptoms. Protalex's
BioRegulators modulate the disease process itself. This approach allows the
biological system to re-establish its inherent control mechanisms in the
complete absence of the toxic side-effects so often associated with
palliation. The Company's approach involves the integration of three stages
of laboratory investigation along with the immediate development of clinical
application. The stages are:
-- The first is an in vitro cell culture system, which allows the
screening of large numbers of compounds for BioRegulator activity.
BioRegulators must initiate or modulate cellular differentiation of
normal cells and re-regulate the same mechanisms in abnormal cells in
both animal and human models in order to qualify for further studies.
-- The second system is in vivo animal models where the BioRegulator must
demonstrate similar process modifying activity at dosage levels,
defined by the cell culture models, which are below any known toxic
-- The third system is also an in vivo model. These animals have either
genetic, or chemically induced arthritis-like, disease. Again, the
BioRegulator must affect the animals' entire physiology in an
integrated fashion. The dosage levels must be similar to those defined
by both the in vitro cell culture system and the in vivo animal models.
The Company can now announce the successful completion of the
identification of a family of BioRegulators which meet all the Company's
criteria. This family of compounds ranges from a natural product to its
active, small molecular weight, subcomponents.
Statements in this press release that are not strictly historical are
"forward-looking" statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.
These statements involve a high degree of risk and uncertainty, are
predictions only and actual events or results may differ materially from those
projected in such forward-looking statements. Factors that could cause or
contribute to differences include the Company's limited operating history,
uncertainty regarding viability and market acceptance of the Company's
products, and the Company's dependence on reimbursement by third parties.
These factors and others are more fully described in the section entitled
"Risks Related to the Company's Business" in the Company's Registration
Statement on Form 10-SB (File No. 000-28385) as filed with the Securities and
SOURCE Protalex Inc.